FDA Approves Imbruvica (ibrutinib) for Chronic Graft Versus Host Disease

August 2, 2017 -- The U.S. Food and Drug Administration today expanded the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments. This is the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news